169.12
前日終値:
$168.52
開ける:
$168.87
24時間の取引高:
550.73K
Relative Volume:
0.46
時価総額:
$17.01B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
26.00
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
+4.82%
1か月 パフォーマンス:
+7.01%
6か月 パフォーマンス:
+17.94%
1年 パフォーマンス:
+35.07%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences Inc
|
169.14 | 16.94B | 3.10B | 668.60M | 831.30M | 6.5044 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.88 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.315 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.28 | 38.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
73.98 | 31.90B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
546.26 | 23.03B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Bull of the Day: Neurocrine Biosciences (NBIX) - Zacks Investment Research
Neurocrine Biosciences, Inc.(NasdaqGS: NBIX) dropped from Russell 1000 Dynamic Index - marketscreener.com
Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed? - Yahoo Finance
Neurocrine Biosciences (NBIX) Unveils New CRENESSITY Data For Classic CAH And Rare Subtype - Yahoo Finance
Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap? - simplywall.st
Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now - Insider Monkey
Neurocrine Biosciences (NBIX): High Growth Stocks to Buy Right Now - Insider Monkey
Neurocrine Biosciences, Inc. Actuals & Estimates (NASDAQ:NBIX) - TradingView
Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June - Investing.com UK
Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June By Investing.com - Investing.com Australia
Price to earnings forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView
Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Price to sales forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Costco Stock And 2 Low Risk Picks Built For Volatile Markets - simplywall.st
Neurocrine Biosciences, Inc. Actuals & Estimates (DUS:NB3) - TradingView
NBIX Forecast — Price Target — Prediction for 2027 - TradingView
NB3 Forecast — Price Target — Prediction for 2027 - TradingView
5 High Growth Stocks to Buy Right Now - Insider Monkey
Neurocrine Biosciences Inc (NBIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Best Momentum Stocks to Buy for June 24th - Yahoo Finance Singapore
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Framework - ChartMill
Neurocrine Biosciences Inc (NBIX) Institutional Confidence - TradingKey
Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
New Strong Buy Stocks for June 24th - Yahoo Finance Singapore
Best Value Stocks to Buy for June 24th - Yahoo Finance Singapore
Neurocrine Biosciences (NBIX) Pe Ratio (TTM) - Zacks Investment Research
What Neurocrine Biosciences (NBIX)'s New CRENESSITY CAH Data Means For Shareholders - Sahm
Stifel reiterates Neurocrine Bio stock rating on Vykat potential By Investing.com - Investing.com Nigeria
Stifel reiterates Neurocrine Bio stock rating on Vykat potential - Investing.com
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 22.8% Potential Upside Amid Strong Growth Prospects - DirectorsTalk Interviews
Neurocrine Biosciences Inc (NBIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentals - ChartMill
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data - simplywall.st
Neurocrine Biosciences Inc (NBIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NBIX News | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine Biosciences Inc (NBIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurocrine Biosciences Inc (NBIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neurocrine Biosciences Inc (NBIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $246 - Moomoo
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate - ChartMill
Neurocrine presents long-term data on Prader-Willi drug By Investing.com - Investing.com South Africa
Neurocrine presents long-term data on Prader-Willi drug - Investing.com
Neurocrine presents case study on Crenessity for rare CAH subtype By Investing.com - Investing.com Australia
Neurocrine presents case study on Crenessity for rare CAH subtype - Investing.com
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire
Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY - StreetInsider
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 - The Grand Junction Daily Sentinel
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):